---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-024305"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2024-03-20T23:59:59+00:00"
generated_at: "2026-06-04T11:47:05.917303+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InMed granted 180-day Nasdaq extension to regain minimum bid compliance

## Summary
- Nasdaq extended compliance period to Sept 16, 2024 to meet $1.00 minimum bid price.
- Must achieve closing bid of $1.00 or more for 10 consecutive business days.
- Previously notified of non-compliance on Sept 19, 2023; original deadline was March 18, 2024.
- Company may consider a reverse stock split if needed; no immediate effect on trading.

## SEC filing metadata
- accession: 0001213900-24-024305
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2024-03-20T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390024024305/0001213900-24-024305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390024024305/ea0202208-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-024305
- JSON: https://secwatch.observer/filing/0001213900-24-024305.json
- Plain text: https://secwatch.observer/filing/0001213900-24-024305.txt

## Key facts
- Listing & Compliance Notices
  InMed Pharmaceuticals Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: March 19, 2024, the Company received written notification (the “Current Notification”) from the Listing Qualifications Department of Nasdaq that the Company has been granted an additional 180-day compliance period, or until September 16, 2024 (the “Extended Compliance Period”), to regain compliance with the Minimum Bid Price Rule. Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390024024305/0001213900-24-024305-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.